SEARCH

SEARCH BY CITATION

References

  • 1
    Bissery MC, Nohynek G, Sanderink GJ, et al. Docetaxel (Taxotere): A review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs 1995;6:339355, 363–338.
  • 2
    National Cancer Institute. Cancer drug information: FDA approval for Docetaxel 2011, January 18, 2011. Available at: http://www.cancer.gov/cancertopics/druginfo/fda-docetaxel. Accessed April 10, 2011.
  • 3
    Simon D, Schoenrock D, Baumgartner W, et al. Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel. J Vet Intern Med 2006;20:11841190.
  • 4
    McEntee MC, Rassnick KM, Bailey DB, et al. Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing cats. J Vet Intern Med 2006;20:13701375.
  • 5
    McEntee M, Silverman JA, Rassnick K, et al. Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. Vet Comp Oncol 2003;1:105112.
  • 6
    McEntee MC, Rassnick KM, Lewis LD, et al. Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs. Am J Vet Res 2006;67:10571062.
  • 7
    Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:195–213.
  • 8
    Thiesen J, Kramer I. Physico-chemical stability of docetaxel premix solution and docetaxel infusion solutions in PVC bags and polyolefine containers. Pharm World Sci 1999;21:137141.
  • 9
    Vail DM. Cancer clinical trials: Development and implementation. Vet Clin North Am Small Anim Pract 2007;37:10331057, v.
  • 10
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205216.
  • 11
    Malingre MM, Richel DJ, Beijnen JH, et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 2001;19:11601166.
  • 12
    Koolen SL, Beijnen JH, Schellens JH. Intravenous-to-oral switch in anticancer chemotherapy: A focus on docetaxel and paclitaxel. Clin Pharmacol Ther 2010;87:126129.
  • 13
    Baker J, Ajani J, Scotte F, et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009;13:4959.
  • 14
    Gendler A, Lewis JR, Reetz JA, et al. Computed tomographic features of oral squamous cell carcinoma in cats: 18 cases (2002–2008). J Am Vet Med Assoc 2010;236:319325.
  • 15
    Wypij JM, Fan TM, Fredrickson RL, et al. In vivo and in vitro efficacy of zoledronate for treating oral squamous cell carcinoma in cats. J Vet Intern Med 2008;22:158163.
  • 16
    Schuette W, Nagel S, Blankenburg T, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005;23:83898395.